Application Nr Approved Date Route Status External Links
ANDA210784 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Ambrisentan Is Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah) (Who Group 1): • To Improve Exercise Ability And Delay Clinical Worsening. Studies Establishing Effectiveness Included Predominantly Patients With Who Functional Class Ii–iii Symptoms And Etiologies Of Idiopathic Or Heritable Pah (60%) Or Pah Associated With Connective Tissue Diseases (34%). Ambrisentan Is An Endothelin Receptor Antagonist Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah) (Who Group 1): To Improve Exercise Ability And Delay Clinical Worsening. Studies Establishing Effectiveness Included Trials Predominantly In Patients With Who Functional Class Ii–iii Symptoms And Etiologies Of Idiopathic Or Heritable Pah (60%) Or Pah Associated With Connective Tissue Diseases (34%).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ambrisentan AMBRISENTAN ZINC538627

Comments